Document and Entity Information Statement [Table] Statement [Line Items] Statement Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Marketable securities Accounts Receivable, Net, Current Accounts receivable, net Inventory, Net Inventories, net Total inventories Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Marketable Securities, Noncurrent Long term marketable securities Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Net book value of intangible assets Other Assets, Noncurrent Other non-current assets Deferred Tax Assets, Net, Noncurrent Deferred income taxes Deferred income taxes (asset) Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Represent the amount of accrued sales deduction. Accrued Sales Deduction Accrued sales deductions Accrued Liabilities, Current Accrued expenses Total Accrued Income Taxes, Current Income taxes payable Current portion of debt due within one year or the normal operating cycle, if longer, related to the sale of future royalties, for which the creditor does not have general recourse to the debtor but rather has recourse only to the property used for collateral in the transaction or other specific property. Non Recourse Debt Sale of Future Royalties Current Non-recourse liability related to sale of future royalties, current portion Contract with Customer, Liability, Current Deferred licensing revenue Liabilities, Current Total current liabilities Contract with Customer, Liability, Noncurrent Deferred licensing revenue, net of current portion Convertible Notes Payable, Noncurrent Carrying value of the convertible notes March 31, 2018 carrying value Convertible notes, net Noncurrent portion of debt, net of the amount due within one year or the normal operating cycle, if longer, related to the sale of future royalties, for which the creditor does not have general recourse to the debtor but rather has recourse only to the property used for collateral in the transaction or other specific property. Non Recourse Debt Sale of Future Royalties Noncurrent Non-recourse liability related to sale of future royalties, long term Other Liabilities, Noncurrent Other non-current liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity Common Stock, Value, Issued Common stock, $0.001 par value, 130,000,000 shares authorized at March 31, 2018 and December 31, 2017; 51,633,991 and 51,314,850 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss, net of tax Retained Earnings (Accumulated Deficit) Accumulated deficit Retained earnings (accumulated deficit) Stockholders' Equity Attributable to Parent Ending balance Beginning balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Consolidated Statements of Earnings Revenues [Abstract] Revenue Revenues Revenues Total revenue Costs and Expenses [Abstract] Costs and expenses Cost of Goods and Services Sold Cost of product sales Research and Development Expense Research and development Selling, General and Administrative Expense Selling, general and administrative Costs and Expenses Total costs and expenses Operating Income (Loss) Operating earnings Nonoperating Income (Expense) [Abstract] Other income (expense) Investment Income, Interest Interest income Interest Expense Interest expense Interest incurred in the period on the non-recourse sale of future royalty liability arrangement that was charged against earnings. Interest Expense Non Recourse Royalty Liability Interest expense-nonrecourse liability related to sale of future royalties Non-cash interest expense on non-recourse liability related to sale of future royalties Noncash interest expense Gain (Loss) on Derivative Instruments, Net, Pretax Changes in fair value of derivative liabilities Gains (Losses) on Extinguishment of Debt Loss on extinguishment of debt Loss on extinguishment of debt Nonoperating Income (Expense) Total other expense Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Earnings before income taxes Income Tax Expense (Benefit) Income tax expense Income tax expense Net Income (Loss) Attributable to Parent Net earnings Net earnings Net income Earnings Per Share, Basic and Diluted [Abstract] Earnings per share Earnings Per Share, Basic Net earnings per share, basic Basic (in dollars per share) Earnings Per Share, Diluted Diluted (in dollars per share) Net earnings per share, diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average number of common shares outstanding Weighted Average Number of Shares Outstanding, Basic Basic (in shares) Weighted average shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Diluted (in shares) Weighted average shares outstanding, diluted Consolidated Statements of Comprehensive Earnings Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive earnings: Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized (loss) gain on marketable securities, net of tax of ($614) and $0, respectively Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive (loss) earnings: Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive earnings Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent Unrealized (loss) gain on marketable securities, tax effect Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net earnings Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net earnings to net cash provided by operating activities: Unrealized Gain (Loss) on Derivatives Change in fair value of derivative liability Depreciation, Depletion and Amortization Depreciation and amortization Amortization of Financing Costs and Discounts Amortization of deferred financing costs and debt discount Investment Income, Net, Amortization of Discount and Premium Amortization of premium/discount on marketable securities Represents revenue from the sale of certain royalty and milestone rights. Revenue From Royalty Agreement Non-cash royalty revenue Share-based Compensation Share-based compensation expense Deferred Income Tax Expense (Benefit) Deferred income tax provision Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventories Amount of increase (decrease) in prepaid expenses, and other current assets. Increase Decrease In Prepaid Deferred Expense And Other Current Assets Prepaid expenses and other current assets Increase (Decrease) in Other Noncurrent Assets Other non-current assets Increase (Decrease) in Accounts Payable Accounts payable The increase (decrease) during the reporting period in the aggregate amount of accrued sales deduction. Increase Decrease In Accrued Sales Deductions Accrued sales deductions Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Income Taxes Payable Income taxes payable Represents the increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting licensing revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Increase (Decrease) in Deferred Licensing Revenue Deferred licensing revenue Increase (Decrease) in Other Noncurrent Liabilities Other non-current liabilities Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities Payments to Acquire Marketable Securities Purchases of marketable securities Proceeds from Sale and Maturity of Marketable Securities Sales and maturities of marketable securities Payments to Acquire Property, Plant, and Equipment Purchases of property, plant and equipment Payments to Acquire Intangible Assets Deferred legal fees Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities Proceeds from Convertible Debt Proceeds from issuance of convertible notes Payment of Financing and Stock Issuance Costs Convertible notes issuance financing costs Debt financing costs Proceeds from Issuance of Warrants Proceeds from sale of warrants Proceeds from issuance of warrants The cash outflow representiong the total cost of the convertible note hedge transactions. Purchases Of Convertible Note Hedge Purchases of convertible note hedges Total cost of the convertible note hedge transactions Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of year Supplemental Cash Flow Information [Abstract] Supplemental cash flow information: Income Taxes Paid, Net Income taxes paid Noncash Investing and Financing Items [Abstract] Non-cash financial activity: The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction as well as the interest make-whole. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Debt Conversion, Converted Instrument And Interest Make Whole Amount Conversion of convertible notes and interest make-whole Represents the non cash expenses related to intangible assets that were capitalized and shown within accrued expenses. Non Cash Capitalized Cost Of Intangible Assets Deferred legal fees included in accounts payable and accrued expenses Organization and Business Nature of Operations [Text Block] Organization and Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Inventories Inventory Disclosure [Text Block] Inventories Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Intangible Assets Intangible Assets Disclosure [Text Block] Intangible Assets Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Convertible Senior Notes Long-term Debt [Text Block] Convertible Senior Notes Summary Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Summary Stockholders' Equity Share-Based Payments Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-Based Payments Earnings per Share Earnings Per Share [Text Block] Earnings per Share Income Taxes Income Tax Disclosure [Text Block] Income Taxes Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Collaboration Agreements Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Marketable Securities, Policy [Policy Text Block] Marketable Securities Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Inventory, Policy [Policy Text Block] Inventories Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Intangible Assets, Finite-Lived, Policy [Policy Text Block] Intangible Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Represent the disclosure of accounting policy for the deferred financing costs. Deferred Financing Costs [Policy Text Block] Deferred Financing Costs Disclosure of accounting policy for preclinical study and clinical trial accruals and deferred advance payments. Preclinical Study and Clinical Trial Accruals and Deferred Advance Payments [Policy Text Block] Preclinical Study and Clinical Trial Accruals Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Trade and Other Accounts Receivable, Policy [Policy Text Block] Accounts Receivable, net Cost of Sales, Policy [Policy Text Block] Cost of Product Sales Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block] Advertising Expense Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-Based Compensation Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Property, Plant and Equipment [Table Text Block] Schedule of average useful lives used to compute depreciation and amortization Disaggregation of Revenue [Table Text Block] Schedule of revenue recognition Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Schedule of impact on financial statements due to adoption of ASC Topic 606 Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of financial instruments Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Schedule of fair value of the financial assets and liabilities Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of unrestricted marketable securities Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of contractual maturities of the unrestricted available for sale marketable securities held Schedule of Inventory, Current [Table Text Block] Schedule of inventories Tabular disclosure of the components of property, plant and equipment. Schedule of Property Plant and Equipment Components [Table Text Block] Schedule of property and equipment Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Schedule of gross carrying amount and related accumulated amortization of the intangible assets Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Convertible Debt [Table Text Block] Summary of liability component of 2023 Notes Schedule of Stockholders Equity [Table Text Block] Schedule of activity in certain captions within Stockholders' Equity Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of share-based compensation recognized related to the grant of employee and non-employee stock options, SAR, Employee Stock Purchase Plan (ESPP) awards and non-vested stock Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option and SAR activity Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of common stock equivalents excluded in the calculation of diluted earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net earnings per share Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] summary of our income tax expense and effective tax rate Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum lease payments under non-cancelable operating leases The number of proprietary commercial products market by the company. Number Of Proprietary Commercial Products Number of proprietary commercial products Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Marketable Securities - Restricted Basis of Presentation [Abstract] Basis of Presentation Number of Operating Segments Number of operating segments Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Computer Equipment [Member] Computer equipment Computer Software Intangible Asset [Member] Software Represents information pertaining to lab equipment and furniture. Lab Equipment And Furniture [Member] Lab equipment and furniture Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Property, Plant and Equipment [Line Items] Property and equipment Property, Plant and Equipment, Useful Life Average useful lives Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Notes payable Debt Instrument, Interest Rate, Stated Percentage [Abstract] Deferred Financing Costs Debt Instrument, Face Amount Principal amount of the 2023 Notes Aggregate principal amount Amount issued Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue Recognition Represents the period within which a product can be returned by the customers to the entity prior to the expiry date. Sales Return Period Prior To Expiration Sales return period prior to expiry date Represents the period within which a product can be returned by the customers to the entity subsequent to the expiry date. Sales Return Period Sales return period subsequent to expiry date Revenue Recognition, Milestone Method, Revenue Recognized Milestone revenue Minimum guaranteed amount owed to company from license and royalty revenue. Minimum Guaranteed Amounts Owed to Company Guaranteed minimum amounts Concentration Risk [Table] Concentration Risk [Line Items] Concentration risk percentage Accounts Receivable, Net [Abstract] Accounts Receivable, Net The period of arrangements are payable from the transfer of the product. Accounts Receivable Collection Period Arrangements payable term Allowance for Doubtful Accounts Receivable Allowance for bad debt Represents the allowance for sales deductions, which may include expected prompt-pay discounts and wholesaler fees. Allowance for Expected Sales deductions Allowance for expected sales discounts Contract with Customer, Asset, Net Contract assets Contract with Customer, Liability Contract liabilities Marketing and Advertising Expense [Abstract] Advertising Expense Advertising Expense Advertising costs New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Recently Issued Accounting Pronouncements Liabilities [Abstract] Liabilities Equity [Abstract] Equity Long-term Debt, Type [Axis] Longterm Debt Type [Domain] Long-term Debt, Type [Domain] Convertible Notes Payable [Member] 0.625% Convertible Senior Notes due 2023 Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Quoted Prices in Active Markets (Level 1) Fair Value Inputs Level2 [Member] Significant Other Observable Inputs (Level 2) Assets, Fair Value Disclosure [Abstract] Assets: Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Marketable Securities, Noncurrent [Abstract] Long term marketable securities: Financial Instruments, Owned, Corporate Debt, at Fair Value Corporate debt securities Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Government debt securities Other Assets, Noncurrent [Abstract] Other non-current assets: Defined Benefit Plan, Assets for Plan Benefits, Noncurrent Marketable securities - restricted (SERP) Assets, Fair Value Disclosure Total assets at fair value The amount of notes estimated at fair value. Notes at Estimated Fair Value Estimated fair value Available-for-sale Debt Securities, Amortized Cost Basis Corporate and government debt securities, Amortized Cost Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Corporate and government debt securities, Gross Unrealized Gains Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax Corporate and government debt securities, Gross Unrealized Losses Available-for-sale Securities, Debt Securities Corporate and government debt securities, Fair Value Corporate debt securities, Fair Value Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract] Contractual maturities of the unrestricted available for sale marketable securities held Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Less Than 1 Year Fair value of available-for-sale debt securities maturing after the first year through the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Available For Sale Securities Debt Maturities After One Through Two Years Fair Value 1 year to 2 years Fair value of available-for-sale debt securities maturing in the second fiscal year through the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value 2 year to 3 years Fair value of available-for-sale debt securities maturing in the third fiscal year through the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value 3 years to 4 years Inventory, Work in Process and Raw Materials, Net of Reserves Raw materials Inventory, Work in Process, Net of Reserves Work in process Inventory, Finished Goods, Net of Reserves Finished goods Leasehold Improvements [Member] Leasehold improvements Property, Plant and Equipment, Gross Property and equipment, gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization expense Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite Lived Intangible Assets Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents [Member] Purchased patents Represents information pertaining to Trokendi XR patent litigation. Trokendi Xr [Member] Trokendi XR patent litigation Represents information concerning the capitalized patent defense costs related to the Watson litigation. Patent Defense Costs [Member] Capitalized patent defense costs Finite-Lived Intangible Assets [Line Items] Intangible Assets Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Weighted-Average Life Finite-Lived Intangible Assets, Gross Gross carrying amount Finite-Lived Intangible Assets, Accumulated Amortization Less accumulated amortization Intangible Assets, Net (Excluding Goodwill) [Abstract] Additional disclosures Represents the number of settlements. Number of Settlements Number of settlements Amortization of Intangible Assets Amortization expense Represents the amount of clinical trial and clinical supply costs accrued. Accrued Clinical Trial and Clinical Supply Costs Current Accrued clinical trial and clinical supply costs Employee-related Liabilities, Current Accrued compensation Represents the amount of product costs accrued. Accrued Product Costs Current Accrued product costs Accrued Professional Fees, Current Accrued professional fees Interest Payable, Current Accrued interest expense Other Accrued Liabilities, Current Other accrued expenses Represents information pertaining to 0.625% Convertible Senior Notes due 2023. Percentage Of0.625 Convertible Senior Notes Due2023 [Member] 2023 Notes Represents information pertaining to the 0.625% Convertible Senior Notes due 2023 that were granted to the initial purchasers. Percentage Of0.625 Convertible Senior Notes Due2023 Granted To Initial Purchasers [Member] Convertible Senior Notes due 2023 granted to initial purchasers Represents information pertaining to the 0.625% Convertible Senior Notes due in 2023 that were granted in the over-allotment option to purchase. Percentage Of0.625 Convertible Senior Notes Due2023 Over Allotment Option [Member] Convertible Senior Notes due 2023 over-allotment option Over-allotment period for additional principal amount for Notes due 2023. Over-allotment period for Additional Principal Amount Over-allotment period for additional principal amount Debt Instrument, Convertible, Threshold Trading Days Threshold trading days (whether or not consecutive) Debt Instrument, Convertible, Threshold Consecutive Trading Days Consecutive trading day period (in days) Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Minimum percentage of the conversion price on trading day Debt Instrument, Convertible, Stock Price Trigger Conversion option stock price trigger Threshold number of specified trading days prior to a conversion date during which principal amount of notes for such trading day was less than specified percentage of product of last reported sale price of common stock, that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature. Debt Instrument Convertible Threshold Trading Days was Less Than Specified Percentage of Product of Last Reported Sale Price of Common Stock Threshold trading days period prior to a conversion date during which principal amount of notes for such trading day was less than 98% of the product of the last reported sale price of common stock Threshold period of specified consecutive trading days prior to a conversion date during which principal amount of notes for such trading day was less than the specified percentage of the product of the last reported sale price of common stock, within which common stock price to conversion price of convertible debt instruments must exceed threshold percentage for a specified number of trading days to trigger conversion feature. Debt Instrument Convertible Threshold Consecutive Trading Days was Less Than Specified Percentage of Product Last Reported Sale Price of Common Stock Consecutive trading day period prior to a conversion date during which principal amount of notes for such trading day was less than 98% of the product of the last reported sale price of common stock The number of equity instrument in shares that the holder of the debt instrument would receive if the debt was converted to equity. Debt Instrument Convertible Number of Equity Instrument in Shares Conversion rate for the Notes (in shares) The principal amount of notes used as denominator for purposes of computing the conversion ratio of convertible debt. Debt Instrument Principal Amount Denominator for Conversion into Common Stock Conversion ratio, principal amount Debt Instrument, Convertible, Conversion Price Conversion price, per share of Common Stock The amount of face value of notes issued. Notes Face Value Amount of principal value to be repaid Debt Conversion, Converted Instrument, Warrants or Options Issued Convertible note hedge options issued (in shares) Class of Warrant or Right, Outstanding Warrants issued Represents the information pertaining to the shares per warrant entitled to holders at strike price. Class of Warrant or Right, Number of Shares in Which Holder Can be Entitled per Warrants at Strike Price Number of shares per warrant entitled to holder Class of Warrant or Right, Exercise Price of Warrants or Rights Strike price of the Warrant Transactions (in dollars per share) Debt Instrument, Interest Rate, Effective Percentage Effective interest rate (as percent) Conversion option that has been reported as an adjustment to additional paid in capital (APIC) including conversion feature and debt discount. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature and Debt Discount Conversion option reported as debt discount and APIC N\a. Debt Instrument Convertible Additional Information [Abstract] Liability component of the 2023 Notes Unamortized Debt Issuance Expense Debt discount Debt Issuance Costs, Net Deferred financing costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Accretion of debt discount and deferred financing costs Debt Conversion, Converted Instrument, Shares Issued Shares of common stock issued in conversion of Notes Debt Conversion, Original Debt, Amount Conversion of debt to equity - principal Cumulative Effect of New Accounting Principle in Period of Adoption Cumulative-effect of adoption of ASC 606 Amount of stockholders' equity, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption. Stockholders' Equity, Adjusted Balance Balance adjusted Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Share-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Exercise of stock options Stock Issued During Period, Value, Conversion of Convertible Securities Equity component of convertible notes issurance, net of tax Purchases of convertible note hedges, net of tax. Purchases Of Convertible Note Hedges Net Of Tax Purchases of convertible note hedges, net of tax Adjustments to Additional Paid in Capital, Warrant Issued Issuance of warrants Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Represents information pertaining to the 2012 Equity Incentive Plan that provides for grants of stock options, purchase rights and awards to employees, officers, directors, consultants or advisors. Equity Incentive Plan2012 [Member] 2012 Plan Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] Employee Stock Option [Member] Stock Option Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based payments Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Maximum number of shares of common stock provided for issuance Represents the number of installments in which the awards would generally vest starting from the first anniversary of the date of grant. Share Based Compensation Arrangement by Share Based Payment Award, Award Vesting Number of Installments from First Anniversary of Grant Date Number of annual installments in which the awards would generally vest starting on the first anniversary of the date of grant Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Contractual term Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research And Development Expense [Member] Research and development Selling General And Administrative Expenses [Member] Selling, general and administrative Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Payments Allocated Share-based Compensation Expense Share-based compensation recognized Represents information related to stock option awards for employees and non-employees as well as stock appreciation rights. Stock Option Stock Appreciation Rights [Member] Stock option and Stock Appreciation Rights Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options and SAR Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at the end of the period (in shares) Outstanding at the beginning of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the end of the period (in dollars per share) Outstanding at the beginning of the period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Weighted-Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Represents stock options, stock appreciation rights and employee stock purchase plan. Stock Options Stock Appreciation Rights And Employee Stock Purchase Plan Awards [Member] Stock options, stock appreciation rights, and ESPP awards Warrant [Member] Warrants to purchase common stock Its represent Convertible notes hedge. Convertible Notes Hedge [Member] Convertible notes hedges Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Income per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common stock equivalents excluded in the calculation of diluted income per share Numerator, in thousands: Net Income (Loss) Available to Common Stockholders, Basic Net earnings used for calculation of basic EPS The amount of interest recognized in the period including interest expense adjustments, associated with any convertible debt. Interest On Convertible Debt Including Adjustments Interest expense on convertible debt The increase (decrease) during the period in the fair value of derivative instruments reported as liabilities. Increase Decrease in Fair Value Derivative Liabilities Changes in fair value of derivative liabilities Difference between the fair value of payments made and the carrying amount of outstanding debt which is extinguished prior to maturity. Gains Losses On Extinguishment of Outstanding Debt Loss on extinguishment of debt Difference between the fair value of payments made and the carrying amount of outstanding debt as if converted which is extinguished prior to maturity. Gains Losses on Extinguishment of Outstanding Debt as if Converted Loss on extinguishment of outstanding debt, as if converted Dilutive Securities, Effect on Basic Earnings Per Share Total adjustments Net income used for calculation of diluted EPS Net earnings used for calculation of diluted EPS Denominator: Effect of dilutive potential common shares: Shares underlying Convertible Senior Secured Notes and interest make-whole Shares underlying Convertible Senior Notes Represents the information relating to shares issuable to settle interest make-whole derivatives. Incremental Common Shares Attributable To Settlement Of Interest Make Whole Derivates Shares issuable to settle interest make-whole derivatives Weighted Average Number of Shares, Employee Stock Ownership Plan Shares Not Committed to be Released Stock options and stock appreciation rights Weighted Average Number Diluted Shares Outstanding Adjustment Total potential dilutive common shares Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective tax rate Effective Income Tax Rate Reconciliation, Percent Effective tax rate Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Excess tax benefits related to employee exercise of stock options Schedule of Related Party Transactions, by Related Party [Table] Number of additional lease term to be extended. Number of Additional Lease Term Number of additional lease term Represents the additional period for which the entity may extend the operating lease term. Operating Leases Optional Lease Extension Period Additional period for which the entity may elect to extend the term of the lease Represents the additional amount of payments that the lessee can elect to make in connection with tenant and capital improvement allowances under the terms of an agreement classified as an operating lease. Operating Leases Additional Allowance for Tenant and Capital Improvement Additional tenant improvement allowance Represents the amount of allowances for tenant and capital improvements that have been utilized and capitalized by the entity. Operating Leases Allowance for Tenant and Capital Improvement Capitalized Tenant improvement allowance utilized and included in fixed assets and deferred rent Represents the amount available for tenant improvements. Operating Leases Amount Available For Tenant Improvements Amount available for tenant improvements Operating Leases, Rent Expense Rent expense Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Future minimum lease payments under non-cancelable operating leases Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2018 (remaining) Operating Leases, Future Minimum Payments, Due in Two Years 2019 Operating Leases, Future Minimum Payments, Due in Three Years 2020 Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Operating Leases Future Minimum Payments Due After Three Years Thereafter Operating Leases, Future Minimum Payments Due Total The potential maximum amount payable upon achievement of certain milestones, under the purchase and sale agreement. Potential Maximum Milestone Payments Payable Potential maximum milestone payments payable The amount of milestone payments due under the purchase and sale agreement. Milestone Payments Due Milestone payments due Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Information by collaborative arrangements. Collaborative Arrangements Transactions [Axis] The collective collaborative arrangements, which are contractual arrangements with a party or parties that both: (i) actively participate in a joint operating activity and (ii) is (are) exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Collaborative Arrangements Transactions [Domain] Collaborative Arrangements Transactions [Domain] Collaborative Arrangement [Member] License and collaboration agreements Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Represents information pertaining to United Therapeutics, with whom the entity has entered into a license agreement. United Therapeutics [Member] United Therapeutics Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaboration agreement Products and Services [Axis] Products And Services [Domain] Products and Services [Domain] Product [Member] Product Represents information pertaining to royalty revenue. Royalty [Member] Royalty Represents information pertaining to Licensing revenue. License [Member] Licensing Adjustments for New Accounting Pronouncements [Axis] Type Of Adoption [Member] Type of Adoption [Domain] Accounting Standards Update201409 [Member] ASU 2014-09 Represents information pertaining to Oxtellar XR product. Oxtellar X R [Member] Oxtellar XR Represents information pertaining to Trokendi XR product. Trokendi X R [Member] Trokendi XR Royalty Agreements [Member] Royalty revenue agreements Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference Between Revenue Guidance In Effect Before And After Topic606 [Member] Effect of Change Higher (Lower) Measurement Basis [Axis] Portion At Fair Value Fair Value Disclosure [Member] Portion at Fair Value Measurement [Member] Carrying Reported Amount Fair Value Disclosure [Member] Total Carrying Value Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Recurring Construction In Progress [Member] Construction in progress Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] Over Allotment Option [Member] Overallotment option Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Retained Earnings (Accumulated Deficit) Title of Individual [Axis] Title Of Individual With Relationship To Entity [Domain] Relationship to Entity [Domain] Director [Member] Directors Convertible Debt Securities [Member] Convertible notes Related Party [Axis] Related Party [Domain] Related Party [Domain] Represents information pertaining to Rockside-700 LLC. Rockside700 L L C [Member] Rockside-700 LLC Pertains to Rune HealthCare Limited (Rune). Rune Healthcare Limited [Member] Rune HealthCare Limited This member represents afecta pharmaceuticals inc. Afecta Pharmaceuticals Inc [Member] Afecta Pharmaceuticals Inc